Company Information

  

Address: 664 CRUISER LANE  
City: BELGRADE 
State: MT 
Zip Code: 59714 
Telephone: 406-388-0480 

Description of Business

Primary SIC Code: 2836
(As filed with the SEC)  

Xtant Medical Holdings, Inc. develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. Xtant believes the following competitive strengths will be key drivers of future growth of Xtant: Portfolio of Proprietary Technologies: Xtant has developed a comprehensive portfolio of products that address a broad array of spinal pathologies, anatomies and surgical approaches in the complex spine and minimally invasive surgery ("MIS") markets.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-1.52NAN/E
03/2017-1.36NAN/E
12/2016-1.54NAN/E
09/20160.22NA5.14
06/2016-0.06NAN/E
03/2016-0.09NAN/E
12/2015-0.24NAN/E
09/2015-2.20NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.23Total Liab/Total Assets1.05
Net Inc/Total Assets-0.14Total Liab/Inv Cap1.48
Net Inc/Inv Cap-0.19Total Liab/Comm Equity1.77
Pretax Inc/Net Sales-0.22Interest Coverage Ratio-0.59
Net Inc/Net Sales-0.22Curr Debt/Equity-1.56
Cash Flow/Net Sales-0.16LTD/Equity-16.97
SG&A/NetSales0.67Total Debt/Equity-18.53
Asset Utilization   Liquidity  
Net Receivables Turnover5.24Quick Ratio0.73
Inventory Turnover1.13Current Ratio1.57
Inventory Day Sales0.00Net Rec/Curr Assets0.39
Net Sales/Work Cap5.04Inv/Curr Assets0.54
Net Sales/PP&E5.35  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 21.41 22.08 24.47 23.09
Cost of Goods Sold 7.88 6.56 6.96 7.11
Selling & Admin Exps 16.14 15.49 16.49 15.17
Operating Income -4.72 -1.95 -1.16 -1.90
Interest Exp 3.33 3.40 3.29 3.16
Pretax Income -9.69 -5.17 -4.49 -4.90
Other Income -1.65 0.18 -0.04 0.17
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -9.69 -5.17 -4.54 -4.90

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 1.66 2.49 2.58 1.41
Receivables - Total 15.85 16.32 18.99 15.83
Inventories - Total 24.93 26.36 26.27 26.50
Total Current Assets 43.28 46.82 48.99 45.77
Net Property, Plant & Equipment 14.68 15.66 16.81 17.28
Total Assets 134.29 139.69 144.10 142.45
Liabilities        
Accounts Payable 20.37 18.18 20.09 19.57
Debt in Current Liabilities 0.48 10.72 11.03 8.90
Total Current Liabilities 20.85 28.90 31.12 28.47
Long-Term Debt 134.74 122.46 120.05 119.08
Total Liabilities 155.59 151.36 151.17 147.55
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -107.39 -97.70 -92.53 -88.00
Treasury Stock NA NA NA NA
Total Stockholders' Equity -21.29 -11.67 -7.07 -5.10
Total Liabilities and Stockholders' Equity 134.29 139.69 144.10 142.45

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -1.19 0.44 -3.21 -3.44
Net Cash Provided by Investing Activities -0.76 -0.31 -0.27 -1.18
Net Cash Provided by Financing Activities 1.13 -0.22 4.65 3.82

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201232.98-7.71--
12/201333.07-12.69--
12/201435.33-10.51--
12/201559.35-2.17-0.24
12/201690.00-19.49-1.54
Growth Rates28.53----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17191,8049.98




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.